Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Chordia Therapeutics Inc. ( (JP:190A) ) just unveiled an update.
Chordia Therapeutics Inc. reported its non-consolidated financial results for the six months ending February 28, 2025, showing a net loss with operating and ordinary profits also in the negative. The company’s total assets and equity ratio have decreased compared to the previous period, indicating financial challenges. Despite these losses, there are no changes in accounting policies or dividend forecasts, and the company maintains a stable number of shares outstanding.
More about Chordia Therapeutics Inc.
Chordia Therapeutics Inc. is a company listed on the Tokyo Stock Exchange, operating in the pharmaceutical industry with a focus on developing therapeutic solutions. The company is led by CEO Hiroshi Miyake and is involved in corporate management and financial reporting.
YTD Price Performance: -25.32%
Average Trading Volume: 1,561,679
Technical Sentiment Signal: Strong Buy
Learn more about 190A stock on TipRanks’ Stock Analysis page.